Krey Steven C, Waise Jeff, Skrupky Lee P
1 Department of Pharmacy, Aurora Medical Center-Grafton, Grafton, WI, USA.
2 Department of Pharmacy, Aurora BayCare Medical Center, Green Bay, WI, USA.
J Pharm Pract. 2019 Apr;32(2):139-146. doi: 10.1177/0897190017743154. Epub 2017 Nov 21.
To improve allergy history documentation and increase the use of beta-lactams when appropriate in patients with a reported beta-lactam allergy.
This pre-post study was conducted at a 167-bed tertiary care community hospital and evaluated multidisciplinary interventions on allergy documentation and antibiotic selection. Interventions included education, creation of local practice guidelines, and modified practices for pharmacists and pharmacy technicians. Inpatients with a reported beta-lactam allergy receiving at least 1 antibiotic for >24 hours were included; first admissions were assessed. Primary outcomes were documentation of reaction type and percentage of patients receiving non-beta-lactam therapy. Secondary outcomes included documentation of previously tolerated beta-lactams, modification of non-beta-lactam therapy, discharge antibiotics, and adverse reactions.
A total of 179 patients were included, 91 preintervention and 88 postintervention. No significant differences were observed between the before versus after groups in the percentage of patients with documentation of reaction type (90.1% vs 89.8%, P = .940) or the overall percentage of patients receiving non-beta-lactams (86.8% vs 84.1%, P = .605). However, significantly more patients in the after phase had documentation of previously tolerated beta-lactams (8.8% vs 28.4%, P = .001), and among patients receiving a non-beta-lactam, a greater percentage was subsequently switched to a beta-lactam (11.4% vs 25.7%, P = .022). One allergic reaction was documented during the study, which occurred in the before phase.
Multidisciplinary education and local guideline implementation led by pharmacists may improve allergy documentation and antibiotic selection in patients with reported beta-lactam allergies.
改善过敏史记录,并在报告有β-内酰胺类药物过敏的患者中,在适当情况下增加β-内酰胺类药物的使用。
这项前后对照研究在一家拥有167张床位的三级社区医院进行,评估了多学科干预对过敏记录和抗生素选择的影响。干预措施包括教育、制定当地实践指南,以及对药剂师和药房技术人员的实践进行改进。纳入报告有β-内酰胺类药物过敏且接受至少一种抗生素治疗超过24小时的住院患者;评估首次入院患者情况。主要结局指标为反应类型的记录情况以及接受非β-内酰胺类治疗的患者百分比。次要结局指标包括既往耐受的β-内酰胺类药物的记录情况、非β-内酰胺类治疗的调整、出院时使用的抗生素以及不良反应。
共纳入179例患者,干预前91例,干预后88例。在反应类型记录的患者百分比方面(90.1%对89.8%,P = 0.940),以及接受非β-内酰胺类药物治疗的患者总体百分比方面(86.8%对84.1%,P = 0.605),干预前后两组之间未观察到显著差异。然而,干预后阶段有更多患者记录了既往耐受的β-内酰胺类药物(8.8%对28.4%,P = 0.001),并且在接受非β-内酰胺类药物治疗的患者中,随后改用β-内酰胺类药物的百分比更高(11.4%对25.7%,P = 0.022)。研究期间记录了1例过敏反应,发生在干预前阶段。
由药剂师主导的多学科教育和当地指南的实施,可能会改善报告有β-内酰胺类药物过敏患者的过敏记录和抗生素选择。